Pfizer issues global market withdrawal of sickle cell disease therapy Oxbryta

Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago.